Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC

Clinical trial NCT06754059 · RECRUITING

Trial details

NCT number: NCT06754059
Sponsor: zhangjie
Status: RECRUITING
Study type: OBSERVATIONAL

HER2-positive Breast Cancer

Start date: 2021-06-01
Primary completion: 2025-12-30
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.